Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure

Atherosclerosis

Volumn 225, Issue 2, 2012, Pages 504-510

  Hsu, Chiao Po ^a,b   Lin, Shing Jong ^a,b   Chung, Ming Yi ^a,b   Lu, Tse Min ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Asymmetric dimethylarginine; Coronary artery disease; Heart failure; Nitric oxide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ANGIOGRAPHY; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TAIWAN; TIME FACTORS; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84869488652     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.09.040     Document Type: Article

References (38)

1. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
2. Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999, 43:542-548.
3. Hasegawa K., Wakino S., Tatematsu S., et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase 2. Circ Res 2007, 101:e2-10.
4. Suda O., Tsutsui M., Morishita T., et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004, 24:1682-1688.
5. Thum T., Tsikas D., Stein S., et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005, 46:1693-1701.
6. Juonala M., Viikari J.S.A., Alfthan G., et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007, 116:1367-1373.
7. Horning B., Arakawa N., Kohler C., Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998, 97:363-368.
8. Usui M., Matsuoka H., Hiroshi M., Ueda S., Okuda S., Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998, 62:2425-2430.
9. von Haehling S., Bode-Böger S.M., Martens-Lobenhoffer J., et al. Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. Clin Pharmacol Ther 2010, 88:506-512.
10. Dückelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 2007, 27:2037-2042.
11. Zairis M.N., Patsourakos N.G., Tsiaousis G.Z., et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart 2012, 98:860-864.
12. Bart B.A., Shaw L.K., McCants C.B., et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997, 30:1002-1008.
13. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003, 24:1912-1919.
14. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease - results from the AtheroGENE study. Circ Res 2005, 97:e53-e59.
15. Meinitzer A., Seelhorst U., Wellnitz B., et al. Asymmetrical dimethylarginine independently predicts total cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen risk and cardiovascular health study). Clin Chem 2007, 53:273-283.
16. Lu T.M., Chung M.Y., Lin M.W., Hsu C.P., Lin S.J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011, 153:135-140.
17. Ma Y.C., Zuo L., Chen J.H., et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:2937-2944.
18. Böger R.H., Maas R., Schulze F., Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality - an update on patients populations with a wide range of cardiovascular risk. Pharmacol Res 2009, 60:481-487.
19. Follath F., Cleland J.G.F., Klein W., Murphy R. Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 1998, 32:1167-1172.
20. Gardner R.S., Ozalp F., Murday A.J., Robb S.D., McDonagh T.A. N-terminal pro-brain natriuretic peptide - a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003, 24:1735-1743.
21. Fischer D., Rossa S., Landmesser U., et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005, 26:65-69.
22. Ito A., Egashira K., Kadokami T., et al. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyper-reactivity to serotonin in pigs. Circulation 1995, 92:2636-2644.
23. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and actively metabolized by dimetylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003, 23:1455-1459.
24. Böger R.H., Bode-Böger S.M., Tsao P.S., Lin P.S., Chan J.R., Cooke J.P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000, 36:2287-2295.
25. Smirnova I.V., Kajstura M., Sawamura T., Goligorsky M.S. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 2004, 287:H782-H790.
26. Jiang D.J., Jia S.J., Dai Z., Li Y.J. Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells. J Mol Cell Cardiol 2006, 40:529-539.
27. von Leitner E.C., Klinke A., Atzler D., et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 2011, 124:2735-2745.
28. Nerheim P., Birger-Botkin S., Piracha L., Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004, 110:247-252.
29. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32:695-703.
30. Cengel A., Sahinarslan A., Biberoĝlu G., et al. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol 2008, 63:33-37.
31. Goette A., Hammwöhner M., Bukowska A., et al. The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 2012, 154:141-146.
32. Visser M., Paulus W.J., Vermeulen M.A., et al. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 2010, 12:1274-1281.
33. Chen Y.J., Li Y.F., Zhang P., et al. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol 2005, 289:H2212-H2219.
34. Chen Y.J., Park S., Li Y.F., et al. Alterations of gene expression in falling myocardium following left ventricular assist device support. Physiol Genomics 2003, 14:251-260.
35. Shao Z., Wang Z., Shrestha K., et al. Pulmonary hypertension associated with advanced systolic heart failure. J Am Coll Cardiol 2012, 59:1150-1158.
36. Hu X., Atzler D., Xu X., et al. Global dimethylarginine dimethylaminohydrolase-1 (DDAH1) gene-deficiency mice reveal that DDAH-1 is the critical enzyme for degrading the cardiovascular risk asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 2011, 31:1540-1546.
37. Schulze F., Lenzen H., Hanefeld C., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter coronary artery risk determination investigating the influence of ADMA concentration (CARDIAC) study. Am Heart J 2006, 52:493.e1-493.e8.
38. Lu T.M., Ding Y.A., Charng M.J., Lin S.J. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 2003, 26:458-464.